Parallel Session 3412

Imaging Parkinsonian Disorders in 2026: What's Next for Neuroimaging

Tuesday, October 6, 2026
14:30 - 16:00 | Conference Room North 203, Level 2

In this session, the faculty will present how imaging markers can track the transition from at-risk to overt motor disease in Parkinson's disease. They will review the evolution of alpha-synuclein PET tracers in an effort to move upstream toward pathology-specific imaging and how alpha-synuclein propagates in the whole brain network. The role of tau PET imaging and distinct tau aggregation patterns in Parkinsonisms will be addressed, along with how amyloid PET and neuroinflammation imaging add further context, offering an integrated view on the current and future applications of imaging modalities.

Chairs:

Cecilia Peralta, Argentina
A. Jon Stoessl, Canada

Presenters:

Neuroimaging Clues of Phenoconversion to Parkinson’s Disease
Jee-Young Lee, Korea

Imaging Alpha-Synuclein: The Next Generation of Imaging Tracers
Hitoshi Shimada, Japan

Imaging Tau and Co-Pathologies in Parkinsonisms: The Next Steps
Antonio Strafella, Canada

CSPC Liaison(s):

Maria Cecelia Peralta, Argentina

Learning Objectives

At the conclusion of this session, participants should be better able to:

1. Evaluate recent evidence linking imaging markers to clinical phenoconversion, from at risk state to motor phenoconversion and disease progression
2. Discuss the state-of-the-art of alpha synuclein imaging tracers development as well as connectome-based models in understanding alpha-synuclein spread across neuronal networks
3. Discuss advances in the imaging of inflammation and non-synuclein protein deposition in parkinsonism relevance

Recommended Audience

Clinician / General Neurology
Fellow / Resident / Student
Industry
Researcher / Basic Science

Education Level

Advanced / Expert
Intermediate / Experienced